AProtein kinase targeted. A number of these molecules are broad-spectrum kinase
inhibitors. BStaurosporine class represents examples of broad-spectrum kinase inhibitors …

Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of
chronic myeloid leukemia (CML) with interferon-α (IFN-α), but CCgRs are rare. The mean …

Abstract The Philadelphia chromosome (Ph), a minute chromosome that derives from the
balanced translocation between chromosomes 9 and 22, was first described in 1960 and …

Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …

BACKGROUND Neutrophilic‐chronic myeloid leukemia (CML‐N) has been described as a
CML variant associated both with a distinctive molecular defect of the Philadelphia …

Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …

Interferon-alfa (IFNα) became the first-line agent for the treatment of chronic myeloid
leukemia (CML) because it prolongs survival significantly compared to conventional …

BACKGROUND AND OBJECTIVES: The most common translocation in chronic myeloid
leukemia (CML) t (9; 22)(q34; q22) produces the BCR/ABL fusion gene. We set up and …

Real‐time reverse‐transcription polymerase chain reaction (RT‐PCR)(qPCR) of the BCR‐
ABL mRNA is a suitable technique to measure the amount of circulating leukemic cells in …

Abstract Imatinib mesylate (STI571), a specific Bcr-Abl inhibitor, has shown a potent
antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients. Early …